Abstract: A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g.

Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.

Abstract: Advantageous isolated morphic Form III of the hemi-sulfate salt of AT-527 that exhibits a faster rate of dissolution over the amorphous form leading to increased bioavailability and thus efficacy for therapeutic administration in a solid dosage form to treat viral indications, as well as processes for its manufacture.

Abstract: A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g.

Abstract: A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g.

Abstract: A vehicle localization system and method includes acquiring, from a first sensor, first data indicative of a first navigation state of a vehicle; acquiring, from a second sensor, second data indicative of an environment in the vicinity of the vehicle; generating, using a processor communicatively coupled to the first sensor and the second sensor, a second navigation state based on matching the second data to a known map of the environment; and, generating, using the processor, a current navigation state based on the first navigation state and the second navigation state.

Abstract: A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Abstract: A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.

Abstract: The present invention provides advantageous high-dose therapeutic compositions and combinations to treat or prevent Dengue virus infections that may be serotype 1, 2, 3 or 4 as well as a process of manufacture.

Abstract: The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

Abstract: Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.

Abstract: Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.

Abstract: A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.

Abstract: The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

Abstract: The present invention is directed to new methods for the treatment of an infection by a virus from the genus Flavivirus, particularly Dengue fever virus, Yellow Fever virus, Zika virus, and West Nile virus, in a host in need thereof, typically a human.

Abstract: A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.

Abstract: A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g.

Abstract: The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.

Abstract: A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.